Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.46 AUD
Change Today +0.01 / 2.22%
Volume 39.5K
As of 11:15 PM 10/1/15 All times are local (Market data is delayed by at least 15 minutes).

immuron ltd (IMC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/15 - A$0.51
52 Week Low
03/31/15 - A$0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMURON LTD (IMC)

Related News

No related news articles were found.

immuron ltd (IMC) Related Businessweek News

No Related Businessweek News Found

immuron ltd (IMC) Details

Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. Its technology platform produces dairy colostrum- derived polyclonal antibodies used to treat a range of diseases, including infectious diseases, cancers, and chronic inflammatory diseases. The company markets Travelan, a product to prevent infection by enterotoxigenic escherichia coli, which is the cause of travelers’ diarrhea. It is also developing IMM 124-E, a product in Phase II clinical trial for the treatment of non-alcoholic steatohepatitis/Type 2 diabetes; IMM 529 for the treatment of clostridium difficile infection; IMM-363 to treat of side effects caused by chemotherapy or radiation; and IMM-160 to reduce tumor size and suppress liver cancer. The company was founded in 1994 and is based in Southbank, Australia.

Founded in 1994

immuron ltd (IMC) Top Compensated Officers

Executive Vice Chairman
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

immuron ltd (IMC) Key Developments

Immuron Limited Reports Audited Financial Results for the Year Ended 30 June 2015

Immuron Limited reported audited financial results for the year ended 30 June 2015. For the year, total operating revenue was $1,123,707 against $1,044,142 for the same period of last year. Loss before income tax was $3,447,951 against $2,544,550 for the same period of last year. Net loss for the period attributable to members was $3,447,951 against $2,544,550 for the same period of last year. Diluted loss per share 4.407 cents against 3.398 cents for the same period of last year. Net cash flows used in operating activities was $3,020,933 against $2,650,577 for the same period of last year. Payment for purchases of plant and equipment was $3,168 against $15,901 for the same period of last year.

Immuron Appoints Peter Anastasiou as Vice Chairman

Immuron Limited announced that current Non-Executive Director Mr. Peter Anastasiou will assume the title of Vice Executive Chairman with immediate effect. Over the past month Mr. Anastasiou has had an increased level of involvement in the company's activities, and his ongoing involvement is required to continue to facilitate the progression of the US market development opportunities, whilst supporting the company's new Chief Executive Officer, Mr. Thomas Liquard, as he settles into his new role.

Immuron Limited Appoints Thomas Liquard as Chief Executive Officer, Effective from August 31, 2015

The Board of Immuron Limited announced the appointment Thomas Liquard as new Chief Executive Officer, will commence on August 31, 2015. Liquard has held various commercialization, product development and leadership roles with large pharma and biotech companies. From 2013 to 2014, Mr. Liquard was Chief Operating Officer (COO) of major Australian biotech company Alchemia Limited before then becoming CEO of the company. From 2004 to 2007, Mr. Liquard served as a Senior Consultant with the Frankel Group, where he specialized in the life sciences.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMC:AU A$0.46 AUD +0.01

IMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMC.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.0x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMURON LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at